Table 1.
Anthropometric and clinical characteristics of the study (NAFLD) and control groups.
| NAFLD | Control | |
|---|---|---|
| No. | 35 | 37 |
| Age (years) | 14.2 ± 2.6 | 14.7 ± 2.6 |
| Height (cm) | 164.5 ± 15 | 171.7 ± 17 |
| Weight (kg) | 80.3 ± 20 | 63.0 ± 16.5 |
| BMI (kg/m2) | 29.3 ± 4.7 | 21.0 ± 3.0 |
| SDS-BMI | 2.2 ± 0.9 | 0.2 ± 0.8 |
| ALT (IU/L) | 66.7 ± 44.8 | 16.2 ± 7.2 |
| AST (IU/L) | 40.0 ± 20.9 | 19.6 ± 6.0 |
| GGT (IU/L) | 45 ± 32 | 21.6 ± 4.2 |
| TG (mg/dL) | 108 ± 52 | 84 ± 44 |
| TC (mg/dL) | 187 ± 53 | 163 ± 34 |
| HDL-C (mg/dL) | 43.7 ± 13 | 46.3 ± 14 |
| LDL-C (mg/dL) | 123 ± 46 | 101 ± 34 |
| hs-CRP (mg/dL) | 0.31 ± 0.2 | 0.17 ± 0.1 |
| Waist circumference | 97.3 ± 12.7 | 73.9 ± 10 |
| Hip circumference | 101 ± 12 | 92.4 ± 10 |
| WHR | 0.96 | 0.82 |
| Fasting glucose (mg/dL) | 82.5 ± 9.8 | 86.0 ± 6.8 |
| Fasting insulin (μIU/mL) | 15.5 ± 8.1 | 13.9 ± 5.9 |
| HOMA-IR | 3.2 ± 1.8 | 3.2 ± 1.5 |
ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyltransferase; TG: triglycerides; TC: total cholesterol; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; hs-CRP: high-sensitivity C-reactive protein; WHR: waist to hip ratio; HOMA-IR: homeostasis model assessment of insulin resistance.